Background Only clinically validated HPV assays can be accepted in cervical cancer
screening. Objectives To update the list of high-risk HPV assays that fulfil the 2009 …

Background Cervical cancer screening tests that identify DNA of the main causal agent, high-
risk human papillomavirus (HPV) types, are more protective than cervical cytology. We …

Objective To evaluate the diagnostic accuracy of high-risk human papillomavirus (hrHPV)
assays on self samples and the efficacy of self sampling strategies to reach underscreened …

Abstract In 2020, approximately 604 127 patients were newly diagnosed with cervical
cancer and 341 831 died of the disease worldwide. Unfortunately, 85–90% of new cases …

Background Molecular tests for detection of human papillomaviruses (HPVs) play a crucial
role in the prevention of cervical cancer, including recently announced elimination efforts …

We conducted a meta‐analysis of test agreement/concordance between human
papillomavirus (HPV) testing in self‐collected vs clinician‐collected samples in 26 studies …

The aim of this review was to explore the status of urine sampling as a liquid biopsy for
noninvasive cancer research by reviewing used preanalytical parameters and protocols. We …

To suit the needs of the human papillomaviruses (HPV) community comprehensively, a
range of commercial HPV tests with different performance characteristics are required. Four …

Background Human papillomavirus (HPV) testing on self-samples represents a great
opportunity to increase cervical cancer screening uptake among under-screened women …

In 2018, there were an estimated 570,000 new cases of cervical cancer globally, with most
of them occurring in women who either had no access to cervical screening, or had not …